
|Videos|February 2, 2017
The Future of Immune Checkpoint Inhibition in Gastric and Esophageal Cancers
Author(s)Geoffrey Y. Ku, MD
Geoffrey Y. Ku, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of immune checkpoint inhibition in gastric and esophageal cancers.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
5


































